Skip to main content
SABCS 2023 HR+/HER2-
Rapid Reactions, Breast Cancer
Primary Analysis of HER2CLIMB-02: Addition of Tucatinib to Trastuzumab Emtansine in Previously Treated Patients with HER2-Positive Metastatic Breast Cancer
Sara M. Tolaney, MD, MPH
Read More
SABCS 2023 HR+/HER2-
Rapid Reactions, Breast Cancer
INAVO120 Phase III Study: Treatment of Patients With PIK3CA-mutant, HR+/HER2- Locally Advanced or Metastatic Breast Cancer With Invavolisib in Combination With Palbociclib and Fulvestrant
Hope S. Rugo, MD
Read More
SABCS 2023 HR+/HER2-
Rapid Reactions, Breast Cancer
Abemaciclib and NSAI for 1L Treatment of HR+/HER2- Advanced Breast Cancer: Long-term Survival Data Reported
Sara M. Tolaney, MD, MPH
Read More
FDA Updates
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Read More
FDA Updates
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Read More
Breast Cancer
The Pharmacist and Patients With HER2-Positive or HER2-Low Metastatic Breast Cancer: Navigating the Treatment Landscape
Read More
Symptom Management Overview, Adverse Events, Infusion Issues
Management of Iron Infusion Reactions
Raluca Laza, PharmD; Meredith Keisler, PharmD, BCOP; Victoria Handy, PharmD, BCOP; Andrea Dickens, PharmD, BCOP
Read More
Cholangiocarcinoma
Key Advances in the Treatment of Patients with BTC in 2023: New Targeted Therapies, Potential Biomarkers, and Combination Strategies
Read More
Cholangiocarcinoma
KEYNOTE-966: Pembrolizumab Combined With GemCis Versus GemCis Alone in Patients With BTC
Read More
Cholangiocarcinoma
Post-hoc Analysis of the ABC-01, -02, and -03 Trials in Patients With Advanced eCCA
Read More
Page 27 of 200
Results 261 - 270 of 1993